Despite the broad and notable anti-tumor activity of anti-PD-1/PD-L1 antibodies, a large proportion of patients still do not respond to anti-PD-1/PD-L1 therapy (primary resistance), and the patients who respond to them would often develop tumor progression again (acquired resistance). The gene discussed is PDCD1; the disease is neoplasm.